

Edus H Warren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6974615/publications.pdf>

Version: 2024-02-01

102
papers

7,832
citations

57719

44
h-index

51562

86
g-index

103
all docs

103
docs citations

103
times ranked

9494
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterologous <sc>SARSâ€CoV</sc>â€2 vaccinations in patients with Bâ€cell lymphoid malignancies. American Journal of Hematology, 2022, 97, .	2.0	2
2	CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells. Nature Communications, 2022, 13, 78.	5.8	8
3	Precision Medicine in Low- and Middle-Income Countries. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 387-402.	9.6	11
4	The Impact of Bâ€cell Directed Therapy on SARSâ€CoVâ€2 Vaccine Efficacy in CLL. British Journal of Haematology, 2022, , .	1.2	11
5	Serial Analysis of the T-Cell Receptor Î²-Chain Repertoire in People Living With HIV Reveals Incomplete Recovery After Long-Term Antiretroviral Therapy. Frontiers in Immunology, 2022, 13, 879190.	2.2	5
6	Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma. Human Vaccines and Immunotherapeutics, 2021, 17, 1882-1896.	1.4	10
7	High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma. JCO Precision Oncology, 2021, 5, 602-612.	1.5	4
8	RNA helicase, DDX3X, is actively recruited to sites of DNA damage in live cells. DNA Repair, 2021, 103, 103137.	1.3	12
9	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematology,the, 2021, 8, e562-e571.	2.2	28
10	Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. Practical Radiation Oncology, 2020, 10, 44-52.	1.1	10
11	A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 170-177.	0.4	13
12	Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 1979-1993.	2.0	17
13	Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma. Blood Cancer Journal, 2019, 9, 77.	2.8	8
14	Eligibility for CAR Tâ€cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL. American Journal of Hematology, 2019, 94, E117-E116.	2.0	19
15	T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective. Biology of Blood and Marrow Transplantation, 2019, 25, 868-882.	2.0	15
16	Outcomes of patients with large Bâ€cell lymphomas and progressive disease following CD19â€specific CAR Tâ€cell therapy. American Journal of Hematology, 2019, 94, E209-E213.	2.0	92
17	Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 390-395.	0.2	6
18	Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity. Journal of Immunology, 2019, 202, 476-483.	0.4	41

#	ARTICLE	IF	CITATIONS
19	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. <i>Clinical Cancer Research</i> , 2018, 24, 3519-3527.	3.2	80
20	Capacity building for hematologic malignancies in Uganda: a comprehensive research, training, and care program through the Uganda Cancer Instituteâ€“Fred Hutchinson Cancer Research Center collaboration. <i>Blood Advances</i> , 2018, 2, 8-10.	2.5	5
21	Abstract 2552: Preclinical development of T-cell receptor therapy targeting the 5T4 tumor antigen on renal cell carcinoma. , 2018, , .		0
22	Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. <i>Blood</i> , 2017, 129, 2693-2701.	0.6	80
23	Tracking the fate and origin of clinically relevant adoptively transferred CD8 ⁺ T cells in vivo. <i>Science Immunology</i> , 2017, 2, .	5.6	68
24	Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. <i>Blood</i> , 2017, 129, 791-798.	0.6	109
25	Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 559-564.	1.1	12
26	Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e87-e90.	0.2	3
27	T-Cell Receptor Sequencing of Kaposi Sarcoma Tumors to Identify Candidate Tumor-Reactive T Cells. <i>Journal of Global Oncology</i> , 2017, 3, 45s-45s.	0.5	0
28	High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis. <i>Blood Advances</i> , 2017, 1, 535-544.	2.5	27
29	High-throughput sequencing reveals novel features of immunoglobulin gene rearrangements in Burkitt lymphoma. <i>Blood Advances</i> , 2017, 1, 1261-1262.	2.5	1
30	Patterns of disease progression in advanced non-small cell lung cancer patients treated with PD-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20607-e20607.	0.8	0
31	Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 2450-2456.	0.6	32
32	Mechanisms of immune evasion and current status of checkpoint inhibitors in nonâ€“small cell lung cancer. <i>Cancer Medicine</i> , 2016, 5, 2567-2578.	1.3	56
33	Genetic risk factors for sclerotic graft-versus-host disease. <i>Blood</i> , 2016, 128, 1516-1524.	0.6	18
34	Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. <i>JCI Insight</i> , 2016, 1, .	2.3	111
35	Dynamics of the Cytotoxic T Cell Response to a Model of Acute Viral Infection. <i>Journal of Virology</i> , 2015, 89, 4517-4526.	1.5	146
36	Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. <i>Blood</i> , 2015, 125, 3193-3201.	0.6	59

#	ARTICLE	IF	CITATIONS
37	Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells. , 2014, 2, 36.		57
38	High-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology. Blood, 2013, 122, 19-22.	0.6	33
39	Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood, 2013, 122, 1341-1349.	0.6	243
40	Laboratory Correlates of Immune Reconstitution At 1-Year Following Related, Unrelated, and Umbilical Cord Blood Hematopoietic Stem Cell Transplantation: Correlation with Survival. Biology of Blood and Marrow Transplantation, 2013, 19, S204-S205.	2.0	0
41	Evolution and Clinical Implications of the T Cell Repertoire Following Cord Blood Transplant. Biology of Blood and Marrow Transplantation, 2013, 19, S201-S202.	2.0	0
42	HLA-F and MHC-I Open Conformers Cooperate in a MHC-I Antigen Cross-Presentation Pathway. Journal of Immunology, 2013, 191, 1567-1577.	0.4	58
43	Phenotypic and Transcriptional Fidelity of Patient-Derived Colon Cancer Xenografts in Immune-Deficient Mice. PLoS ONE, 2013, 8, e79874.	1.1	34
44	Abstract B49: Autologous T cell responses against patient-derived colorectal cancer xenografts.. , 2013, , .		0
45	Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer. Journal of Immunotherapy, 2012, 35, 131-141.	1.2	45
46	CD8+ T-cell Clones Specific for the 5T4 Antigen Target Renal Cell Carcinoma Tumor-initiating Cells in a Murine Xenograft Model. Journal of Immunotherapy, 2012, 35, 523-533.	1.2	8
47	Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood, 2012, 119, 5311-5319.	0.6	92
48	Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood, 2012, 120, 2796-2806.	0.6	84
49	Diversifying the MHC peptide portfolio. Blood, 2012, 120, 3165-3167.	0.6	1
50	Applications of Next-Generation Sequencing to Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, S151-S160.	2.0	20
51	Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood, 2012, 119, 5492-5501.	0.6	66
52	Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. Expert Opinion on Biological Therapy, 2011, 11, 763-773.	1.4	8
53	Graft versus Leukemia Reactivity after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, S33-S38.	2.0	55
54	A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1308-1315.	2.0	17

#	ARTICLE	IF	CITATIONS
55	Activation and Expansion of CD8+ T Effector Cells in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1121-1132.	2.0	17
56	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <i>Blood</i> , 2011, 117, 3214-3219.	0.6	544
57	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 456-463.	0.6	75
58	Blazing a trail in T-cell recognition. <i>Blood</i> , 2011, 117, 4681-4682.	0.6	0
59	Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2010, 17, 483-492.	1.2	45
60	Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. <i>Blood</i> , 2010, 115, 3869-3878.	0.6	230
61	Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. <i>Blood</i> , 2010, 115, 4923-4933.	0.6	98
62	Abnormalities of the $\hat{1}\hat{2}$ T-cell receptor repertoire in advanced myelodysplastic syndrome. <i>Experimental Hematology</i> , 2010, 38, 202-212.	0.2	17
63	NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 565-586.	2.0	107
64	Overlap and Effective Size of the Human CD8 ⁺ T Cell Receptor Repertoire. <i>Science Translational Medicine</i> , 2010, 2, 47ra64.	5.8	374
65	HLA and TCR Knockout by Zinc Finger Nucleases: Toward <i>à€œoff-the-Shelfà€•</i> Allogeneic T-Cell Therapy for CD19+ Malignancies. <i>Blood</i> , 2010, 116, 3766-3766.	0.6	10
66	Abstract 4778: Epigenetic modulation of colorectal cancer cells for cancer-testis antigen-targeted immunotherapy. , 2010, , .		0
67	Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2009, 15, 4759-4768.	3.2	41
68	Genetic risk for colitis-associated colorectal cancer. <i>Gut</i> , 2009, 58, 1177-1179.	6.1	2
69	Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. <i>Nature Genetics</i> , 2009, 41, 1341-1344.	9.4	91
70	Improving Hematopoietic Cell Transplant Outcomes in a New Era of Genomic Research. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 42-45.	2.0	13
71	Effects of Mismatching for Minor Histocompatibility Antigens on Clinical Outcomes in HLA-Matched, Unrelated Hematopoietic Stem Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 856-863.	2.0	47
72	Comprehensive assessment of T-cell receptor $\hat{2}$ -chain diversity in $\hat{1}\hat{2}$ T cells. <i>Blood</i> , 2009, 114, 4099-4107.	0.6	1,016

#	ARTICLE	IF	CITATIONS
73	Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. <i>Blood</i> , 2009, 114, 702-708.	0.6	218
74	Identification of Novel MHC Class II-Restricted Male-Specific mHAg Encoded by SMCY (JARID1D)... <i>Blood</i> , 2009, 114, 1344-1344.	0.6	7
75	Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1380-1384.	2.0	49
76	<i>C19orf48</i> Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 5260-5269.	3.2	59
77	DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. <i>Blood</i> , 2008, 111, 4817-4826.	0.6	62
78	Generation of CD8+ Cytotoxic T Cell Clones Recognizing BMI1-Derived Peptides. <i>Blood</i> , 2008, 112, 2909-2909.	0.6	2
79	A Single Minor Histocompatibility Antigen Encoded by UGT2B17 and Presented by Human Leukocyte Antigen-A*2902 and -B*4403. <i>Transplantation</i> , 2007, 83, 1242-1248.	0.5	35
80	Adoptive Transfer of Allogeneic Antigen-Specific T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 9-12.	2.0	39
81	The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. <i>Blood</i> , 2006, 107, 3779-3786.	0.6	99
82	Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2006, 107, 2294-2302.	0.6	314
83	Minor histocompatibility antigens in allogeneic hematopoietic cell transplantation. <i>Current Opinion in Organ Transplantation</i> , 2006, 11, 31-36.	0.8	2
84	An Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order. <i>Science</i> , 2006, 313, 1444-1447.	6.0	187
85	Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning. <i>Clinical Cancer Research</i> , 2004, 10, 7799-7811.	3.2	89
86	A Novel HLA-A*3303-Restricted Minor Histocompatibility Antigen Encoded by an Unconventional Open Reading Frame of Human TMSB4Y Gene. <i>Journal of Immunology</i> , 2004, 173, 7046-7054.	0.4	56
87	Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. <i>Blood</i> , 2004, 103, 347-352.	0.6	225
88	The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. <i>Blood Reviews</i> , 2003, 17, 153-162.	2.8	66
89	Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. <i>British Journal of Haematology</i> , 2003, 123, 671-675.	1.2	49
90	A Human Minor Histocompatibility Antigen Resulting from Differential Expression due to a Gene Deletion. <i>Journal of Experimental Medicine</i> , 2003, 197, 1279-1289.	4.2	208

#	ARTICLE	IF	CITATIONS
91	Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. <i>Blood</i> , 2002, 100, 1201-1207.	0.6	278
92	T-Cell Therapy of Leukemia. <i>Cancer Control</i> , 2002, 9, 114-122.	0.7	33
93	Non-Myeloablative Transplants for Malignant Disease. <i>Hematology American Society of Hematology Education Program</i> , 2001, 2001, 375-391.	0.9	98
94	Determination of Intronic Sequences Adjacent to an Exon Using Polymerase Chain Reaction and Genomic DNA Library Constructed by TA Cloning. <i>Analytical Biochemistry</i> , 2001, 289, 289-292.	1.1	1
95	The Immunogenicity of a New Human Minor Histocompatibility Antigen Results from Differential Antigen Processing. <i>Journal of Experimental Medicine</i> , 2001, 193, 195-206.	4.2	191
96	The Human UTY Gene Encodes a Novel HLA-B8-Restricted H-Y Antigen. <i>Journal of Immunology</i> , 2000, 164, 2807-2814.	0.4	161
97	Adoptive Immunotherapy of Human Diseases with Antigen-Specific T-Cell Clones. , 2000, , 29-44.		0
98	Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. <i>Current Opinion in Hematology</i> , 1998, 5, 429-433.	1.2	76
99	Cytotoxic T-Lymphocyteâ€œDefined Human Minor Histocompatibility Antigens With a Restricted Tissue Distribution. <i>Blood</i> , 1998, 91, 2197-2207.	0.6	224
100	Effects of contralateral sound on auditory-nerve responses. II. Dependence on stimulus variables. <i>Hearing Research</i> , 1989, 37, 105-121.	0.9	112
101	Effects of contralateral sound on auditory-nerve responses. I. Contributions of cochlear efferents. <i>Hearing Research</i> , 1989, 37, 89-104.	0.9	223
102	The Human Graft-versus-Tumor Responseâ€œ and How to Exploit It. , 0, , 232-247.		1